6533b821fe1ef96bd127adcf
RESEARCH PRODUCT
C1-02: Randomized Phase II study of vandetanib alone or in combination with carboplatin and paclitaxel as 1st-line treatment for advanced NSCLC
John V. HeymachLuis Paz-aresBruce E. JohnsonMartin SebastianWilfried EberhardtDavid J. StewartPeter LangmuirFilippo De BraudRoy S. HerbstAnnetta D. Krebssubject
Pulmonary and Respiratory MedicineOncologymedicine.medical_specialtybusiness.industryPhases of clinical researchVandetanibCarboplatinchemistry.chemical_compoundOncologyPaclitaxelchemistryInternal medicinemedicineLine (text file)businessmedicine.drugyear | journal | country | edition | language |
---|---|---|---|---|
2007-08-01 | Journal of Thoracic Oncology |